Biochemistry Department, Faculty of Science, Ain Shams University, Abbassia, Cairo, 11566, Egypt.
Med Oncol. 2010 Dec;27(4):1246-53. doi: 10.1007/s12032-009-9366-x. Epub 2009 Nov 24.
Ovarian cancer remains a highly lethal disease. The aim of the present study was to evaluate the usefulness of measuring serum matrix metalloproteinase-7 (MMP-7), CC chemokine ligand 18 (CCL18) and CC chemokine ligand 11 (CCL11) in comparison with serum cancer antigen 125 (CA 125) for diagnosis of epithelial ovarian cancer (EOC). This study included 51 patients with EOC, 27 patients with benign ovarian lesions and 29 healthy volunteers. Serum CA 125 was determined by microparticle enzyme immunoassay, while serum MMP-7, CCL18 and CCL11 were measured using enzyme-linked immunosorbent assay. The sensitivity and specificity were 86.3% and 92.9% for CA 125, 80.4% and 87.5% for MMP-7, 84.3% and 91.1% for CCL18 and, 68.6% and 62.5% for CCL11. Combination of CA 125, MMP-7, CCL18 and CCL11 gave a promising sensitivity of 100%, but specificity was decreased to 60.7%. The combined use of serum CA 125, MMP-7, CCL18 and CCL11 effectively detected early stages EOC with high sensitivity of 94.4%. Our data indicate that serum MMP-7, CCL18 and CCL11, in combination with CA 125 could be useful in diagnosis of EOC.
卵巢癌仍然是一种高度致命的疾病。本研究旨在评估测量血清基质金属蛋白酶-7（MMP-7）、CC 趋化因子配体 18（CCL18）和 CC 趋化因子配体 11（CCL11）与血清癌抗原 125（CA 125）相比在诊断上皮性卵巢癌（EOC）中的有用性。本研究纳入了 51 例 EOC 患者、27 例良性卵巢病变患者和 29 名健康志愿者。采用微粒子酶免疫分析法测定血清 CA 125，采用酶联免疫吸附试验测定血清 MMP-7、CCL18 和 CCL11。CA 125 的敏感性和特异性分别为 86.3%和 92.9%，MMP-7 为 80.4%和 87.5%，CCL18 为 84.3%和 91.1%，CCL11 为 68.6%和 62.5%。CA 125、MMP-7、CCL18 和 CCL11 的联合应用具有 100%的有前途的敏感性，但特异性降低至 60.7%。联合使用血清 CA 125、MMP-7、CCL18 和 CCL11 可有效检测早期 EOC，敏感性高达 94.4%。我们的数据表明，血清 MMP-7、CCL18 和 CCL11 与 CA 125 联合使用可能有助于诊断 EOC。
